The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase I trial combining ipilimumab + high dose stereotactic radiation: Results and serum immune correlates.
 
Chad Tang
No Relationships to Disclose
 
James William Welsh
Stock and Other Ownership Interests - Checkmate Pharmaceuticals; Healios; MolecularMatch; Oncorena; Reflexion Medical
Consulting or Advisory Role - MolecularMatch
Research Funding - Bristol-Myers Squibb; GlaxoSmithKline; Incyte; Merck; miRNA Therapeutics; Varian Medical Systems
 
Patricia de Groot
No Relationships to Disclose
 
Erminia Massarelli
Consulting or Advisory Role - Nektar
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Merck (Inst)
 
Joe Y. Chang
No Relationships to Disclose
 
Kenneth R. Hess
Travel, Accommodations, Expenses - Angiochem
 
Michael A. Curran
Stock and Other Ownership Interests - CytomX Therapeutics; Esperance Pharmaceuticals; Threshold Pharmaceuticals
Consulting or Advisory Role - Advaxis; Agenus; BIND Therapeutics; Calithera Biosciences; Emergent BioSolutions; Infinity Pharmaceuticals
 
Maria E. Cabanillas
No Relationships to Disclose
 
Vivek Subbiah
No Relationships to Disclose
 
Siqing Fu
No Relationships to Disclose
 
Apostolia Maria Tsimberidou
Research Funding - Baxter (Inst); EMD Serono (Inst); Foundation Medicine (Inst); ONYX (Inst)
 
Daniel D. Karp
No Relationships to Disclose
 
Daniel Richard Gomez
Research Funding - Merck
Travel, Accommodations, Expenses - procure
 
Ritsuko Komaki
No Relationships to Disclose
 
Padmanee Sharma
Leadership - Evelo Therapeutics; Jounce Therapeutics; Jounce Therapeutics (I); Neon Therapeutics (I); SAB-Pharma; SAB-Pharma (I)
Stock and Other Ownership Interests - Evelo Therapeutics; Jounce Therapeutics; Jounce Therapeutics (I); Kite, a Gilead company; Kite, a Gilead company (I); Neon Therapeutics (I)
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline
Research Funding - AstraZeneca; Bristol-Myers Squibb; GlaxoSmithKline
Patents, Royalties, Other Intellectual Property - Own patent licensed to Jounce; Own patents licensed to BMS, Jounce & Merck (I)
 
Aung Naing
Research Funding - Amplimmune; ARMO BioSciences; Atterocor; Baxter (I); EMD Serono; Healios; Incyte; Karyopharm Therapeutics; MedImmune; Novartis; Regeneron
Travel, Accommodations, Expenses - ARMO BioSciences
 
David S. Hong
Research Funding - AstraZeneca; Eisai; Genentech; miRNA Therapeutics; Novartis; Pfizer